Company profile for Aurinia Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerularsclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye s...
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerularsclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Our highly skilled leadership team has a proven track record of success. Together they possess more than 200 years of combined corporate and industry specific experience.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
#1203-4464 Markham Street Victoria, BC V8Z 7X8
Telephone
Telephone
+1 (250) 744-2487
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251103166461/en/Aurinia-Pharmaceuticals-to-Report-Financial-Results-for-the-Three-and-Nine-Months-Ended-September-30-2025-and-Provide-Update-on-Recent-Business-Progress-on-November-4-2025

BUSINESSWIRE
03 Nov 2025

https://www.businesswire.com/news/home/20251015580814/en/Aurinia-Announces-Upcoming-Presentations-of-New-Data-on-LUPKYNIS-at-American-College-of-Rheumatology-Convergence-and-American-Society-of-Nephrology-Kidney-Week-2025

BUSINESSWIRE
15 Oct 2025

https://www.fiercepharma.com/pharma/fdas-cder-chief-challenges-safety-efficacy-aurinias-lupus-med-deleted-linkedin-post

FIERCE PHARMA
30 Sep 2025

https://www.businesswire.com/news/home/20250929618760/en/Aurinia-Responds-to-Now-Retracted-LinkedIn-Post

BUSINESSWIRE
29 Sep 2025

https://www.businesswire.com/news/home/20250731800519/en/Aurinia-Pharmaceuticals-Reports-Financial-Results-for-the-Three-and-Six-Months-Ended-June-30-2025

BUSINESSWIRE
31 Jul 2025

https://www.businesswire.com/news/home/20250722543875/en/Aurinia-Pharmaceuticals-to-Release-Second-Quarter-2025-Financial-and-Operational-Results-on-July-31-2025

BUSINESSWIRE
22 Jul 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty